SKIA Information

SKIA is a biotech-focused holding company built on a simple conviction: some of the most valuable biology in medicine is hiding in plain sight. Assets stranded by a lead program's failure, deprioritized inside large pharma, or locked in companies that can no longer fund them are routinely passed over — not because the science is weak, but because they are caught up in complexity. Some of the industry's biggest blockbusters began exactly this way. We operate a hub-and-spoke model that turns these dislocations into opportunity. From a central hub, SKIA identifies and acquires differentiated assets, funds the early work to define their strategy, and builds them into focused, single-therapeutic-area portfolio companies — each with its own management team, board, and path to value. The result is two-dimensional diversification: across multiple therapeutic areas, and within each company's pipeline over time. SKIA retains meaningful ownership throughout, aligning our interests directly with those of our investors. What sets us apart is the team. Our founders and operators bring more than 30 years each of investment, operating, and transaction experience — collectively $25B+ in value generated, $5B+ in capital raised, and 180+ M&A transactions across 15+ therapeutic areas, including company builds and exits such as Arena, Aimmune, Longboard, and Madrigal. That pattern recognition is now amplified by Lodestar™, our proprietary AI platform, which screens the universe of overlooked biology against the selection criteria that built our track record — with every recommendation curated by our team. Our first portfolio company, Skiaphos Hematology, is advancing a differentiated oral program in acute myeloid leukemia, with additional assets in incubation.